Infertility

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
Thursday, April 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

FzioMed, Inc. to Showcase its Women's Health Adhesion Barrier Products at Hysteroscopy, Assisted Reproductive Technology and Ultrasound (HARTUS) Congress

Retrieved on: 
Tuesday, April 16, 2024
Adhesion, Curettage, Pain, Ovary, Congress, Refrigeration, Safety, Pregnancy, Risk, Tissue, Infertility, Federico, Marketing, Doctor of Philosophy, Obstetrics, Gynaecology, Hysteroscopy, Teaching hospital, Patient satisfaction, SAN, Medical director, The Company, Gel

The Company will showcase its innovative Oxiplex® adhesion barrier gel product portfolio designed to reduce the formation of post-surgical adhesions following hysteroscopic and laparoscopic surgery.

Key Points: 
  • The Company will showcase its innovative Oxiplex® adhesion barrier gel product portfolio designed to reduce the formation of post-surgical adhesions following hysteroscopic and laparoscopic surgery.
  • Based on a patented formulation and more than 20 years of use, these barrier products provide a temporary, mechanical separation of tissues during the normal healing process, reducing adhesion formation.
  • "Formulated specifically for intrauterine procedures, our Oxiplex/IU Adhesion Barrier Gel works in concert with the natural healing process to reduce adhesion formation.
  • The Oxiplex portfolio of adhesion barrier products has been available since 2002 and have been used in nearly 1 million procedures worldwide.

Amid threats to IVF, National Infertility Awareness Week® Brings Awareness Activities Across the Country

Retrieved on: 
Monday, April 15, 2024
CVS, Fertility, NIAW, Social media, Woman, Infertility, Human services, Merck Serono, Encompass, IVF, Family, Ferring Pharmaceuticals, Legislation, Movement, Face, First, The Cooper Companies, Birth control

MCLEAN, Va., April 15, 2024 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week®, April 21 through April 27, 2024. The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families. RESOLVE will rally the infertility community to share their stories in an effort to raise awareness about the threats to family building options like IVF, the lack of access to family building options and the need for emotional support for the 1 in 6 people who will face infertility. #LeaveYourMark is a message found on the official NIAW website and throughout RESOLVE's social media campaigns.

Key Points: 
  • RESOLVE: The National Infertility Association will recognize National Infertility Awareness Week®, April 21 through April 27, 2024.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.
  • MCLEAN, Va., April 15, 2024 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week® , April 21 through April 27, 2024.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.

Institute for Human Reproduction (IHR), a Leading Fertility Center in the Midwest with Offices in IL, IN, and WI, Honors National Infertility Awareness Week with a Free IVF Cycle Lottery

Retrieved on: 
Monday, April 15, 2024
IHR, NIAW, Lottery, Infertility, AMH, Insurance, Reproduction, History, IVF, Family, Journey, Physician, Pinnacle, Movement, Birth control

This initiative is designed to shine a light on infertility issues while offering hope and support to those struggling to build their families.

Key Points: 
  • This initiative is designed to shine a light on infertility issues while offering hope and support to those struggling to build their families.
  • Participants must also like the Institute for Human Reproduction on Facebook and follow @IHRfertility on Instagram.
  • The lucky recipient will receive a free IVF cycle, offering a significant opportunity towards achieving their dream of family.
  • For more information on the free IVF cycle Lottery, including detailed eligibility criteria and the entry form, please visit IHRfertility.com/ivf-lottery .

Family Source Consultants Partners with Worth the Wait Charity to Support Young Adult Cancer Patients & Survivors Pursuing Parenthood

Retrieved on: 
Thursday, April 11, 2024
Family, Cancer, Worth, Hysterectomy, Wait, Hope, Infertility, Reproduction, Fertility preservation, FSC, Uterine cancer, Insurance, Partnership, Fertility, Testicular cancer, Parent, IVF, Survivor, Patient, Food, Music, Consultant, Young adult, Birth control

CHICAGO, April 10, 2024 /PRNewswire-PRWeb/ -- This coming September, leading surrogacy agency Family Source Consultants (FSC) will serve as a main sponsor for a fundraising event in support of Worth the Wait Charity. The non-profit organization is dedicated to assisting young adult cancer patients and survivors start their family, many of whom struggle with infertility following treatment. Worth the Wait Charity provides grants to help offset the costs of building families through fertility preservation, adoption, fertility treatments and surrogacy.

Key Points: 
  • This support will make a world of difference in helping ease the financial burden for young adult cancer survivors pursuing parenthood.
  • All proceeds from Jeep Off Cancer will directly support Worth the Wait Charity's mission of aiding young adult cancer patients and survivors on their journey to parenthood.
  • This support will make a world of difference in helping ease the financial burden for young adult cancer survivors pursuing parenthood."
  • "Family Source Consultants couldn't be more eager to support Worth the Wait Charity's Jeep Off Cancer event," said Swiderski.

Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

Retrieved on: 
Thursday, April 4, 2024
Foreign policy, Empire, Infertility, Face, Disease, Empathy, Education, IVF, Fertility, Evite, Family, Movement, Birth control

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, and RESOLVE : The National Infertility Association today announced a series of nationwide events to commemorate National Infertility Awareness Week (April 21-27, 2024).

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, and RESOLVE : The National Infertility Association today announced a series of nationwide events to commemorate National Infertility Awareness Week (April 21-27, 2024).
  • "National Infertility Awareness Week sheds light on the profound impact of infertility, promoting compassion, empathy, and solidarity for the countless individuals struggling to build their family," said Pete Anevski, CEO of Progyny.
  • This will be the third consecutive year the Empire State Building will be lit to support those faced with infertility.
  • "Being an advocate for others navigating their journey, I am deeply honored to participate in National Infertility Awareness Week alongside Progyny and RESOLVE,” says Iskra Lawrence.

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Woman, Male, FDA, Infertility, Insemination, Pharmaceutical industry

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.

Key Points: 
  • ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.
  • Following FDA clearance of FemaSeed, the Company’s revolutionary approach to artificial insemination, Femasys announced completion of enrollment in pivotal trial in support of commercial launch
    Appointed Richard Spector as Chief Commercial Officer and James Liu, M.D.
  • Notably, the majority of women who became pregnant did so after the first FemaSeed procedure,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “Our focus is now on executing on commercialization of FemaSeed and our other available products, as well as advancing the clinical pivotal trial for FemBloc.

Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 27, 2024
Financial statement, Growth, Infertility, International, IVF, Travel, EDT, Acquisition, Laboratory, Consumables, Adjustment, Investment, Depreciation, Analysis, Marketing, Hand, Bookkeeping

Results of Operations for the Year ended December 31, 2023

Key Points: 
  • Results of Operations for the Year ended December 31, 2023
    Hamilton Thorne sales increased 16% to $67,225,476 for the year-ended December 31, 2023, an increase of $9,047,409 from $58,178,067 during the previous year.
  • Consumable sales in 2023 outpaced the Company’s overall growth despite being affected by the recall of certain products by one of the Company’s contract manufacturers.
  • We are expecting first quarter 2024 reported revenues of between $19.0 to 19.4M, with organic growth for the quarter of approximately 8%.
  • Financial Statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Deafness, CDMO, Obesity, Syndrome, Infertility, Entrepreneurship, Disease, Diabetes, Ciliopathy, Patient, CRL, DNA, Display resolution, Kidney disease, GMP, Tecmar, Therapy, Paratriathlon, BBS, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .
  • Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
  • Dysfunctional cilia can cause blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services.

Social media will tell you birth control causes mental health issues, weight gain and infertility – here are the facts

Retrieved on: 
Tuesday, April 9, 2024
Research, Depression, Health, Friends, Faculty, Birth, Infertility, Intrauterine device, Menstrual cycle, Depo, Weight gain, Patient, IUD, Birth control, Social media, Mental health, Fertility, Medroxyprogesterone acetate, Life, Quarterlife, Adolescence, Systematic review, Woman, Progesterone, Family

Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.

Key Points: 
  • Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.
  • These three common misconceptions about birth control are cropping up online and need to be put in context:

1. Contraception causes depression

  • Countless videos on social media discuss the effect hormonal contraceptives have on mental health – with some creators claiming birth control causes mood changes and even depression.
  • Although there’s some correlation between mental health and some forms of contraception, there are many factors at play.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
  • The evidence suggests depression is more common in adolescent girls – and diminishes after the first two years of taking these forms of birth control.
  • At present, there’s little conclusive evidence that contraception (both hormonal and non-hormonal types) cause mental health problems.

2. Contraception causes weight gain

  • Another common social media claim is that birth control causes weight gain.
  • There is one form of contraception that is linked to weight gain.
  • The Depo-Provera injection, which is administered every 12 weeks, has been proved to cause weight gain.


This weight gain may be due to the progesterone in the shot, which can cause people to feel hungrier – potentially leading to overeating and weight gain. If you’re concerned about potential weight gain, the injection is not the only form of contraception available. Other forms of hormonal and non-hormonal contraceptives have not been shown to affect your weight.

3. Birth control lowers your fertility

  • Another common claim on social media is that birth control causes fertility issues.
  • Research shows hormonal contraceptives have no affect on fertility.
  • Again, evidence shows that IUDs pose no risk to fertility.
  • A systematic review reports no specific differences in fertility between hormonal and non-hormonal IUDs.


Christopher O'Sullivan does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.